Concurrent enrollment on a non-chemotherapy treatment trial will be allowed, as long as that trial allows concurrent daily aspirin use
Concurrent therapy with any other investigational drug
Patients may not receive any cancer-directed concurrent therapy, such as concurrent chemotherapy, radiotherapy, or hormonal therapy while on study
Concurrent administration of other anti-cancer therapy during the course of this study is not allowed; note that concurrent use of supportive care medications (e.g. anti-resorptive agents, pain medications) is allowed
Concurrent administration of other cancer specific therapy during the course of this study is not allowed
Concurrent administration of other cancer specific therapy during the course of this study is not allowed
The subject must have completed RT with concurrent TMZ at least 12 weeks prior to the planned start of treatment on this study UNLESS there is pathological verification of recurrent tumor and at least 4 weeks have elapsed since the end of RT with concurrent TMZ.
Concurrent administration of other cancer specific therapy during the course of this study is not allowed
Participation in another concurrent treatment protocol
Any concurrent medications which could interfere with the trial
Concurrent serious infection
Concurrent treatment with any chemotherapeutic agent
MEDICAL HISTORY AND CONCURRENT DISEASES
Concurrent brain-directed therapy
Enrollment in a concurrent clinical study.
Concurrent treatment with non-permitted drugs and other interventions.
Concurrent radiation sensitizing medications concurrent with radiation, per treatment physician
Prior/concurrent radiation therapy allowed
Concurrent treatment with any chemotherapeutic agent.
Concurrent treatment with a non-permitted drug
Concurrent enrollment on another investigational therapy
Concurrent treatment with any other anti-leukemia agent
Concurrent treatment with a non-permitted drug
Concurrent disease - patients under treatment for concurrent medical conditions will be eligible for protocol treatment if, in the opinion of the physician responsible for hyperthermia treatment that the concurrent medical condition will neither interfere with the process of the treatment or patient assessments nor add significantly to the risks or complications of the treatment
Concurrent administration of any other anti-tumor therapy
Patients who are participating in a concurrent treatment protocol
Patients who are participating in a concurrent treatment protocol
SECOND COHORT: Concurrent therapy with enzalutamide will be permitted and is a requirement for enrollment
Note: Concurrent and/or adjuvant chemotherapy does not make a patient ineligible; participation in a concurrent treatment protocol does not make a patient ineligible
Concurrent treatment with another anti-estrogen
Patient with any significant concurrent illness
Concurrent use of bosentan
Concurrent administration of any other antitumor therapy.
Participation in another concurrent treatment protocol
The presence of a concurrent non-appendiceal metastatic cancer
Must be no anticipated need for concurrent radiation therapy during protocol treatment.
Participation in another concurrent treatment protocol
Planned concurrent WBRT
Medical history and concurrent diseases:
Concurrent serious infection
Patients who are participating in a concurrent treatment protocol
See Disease Characteristics PRIOR CONCURRENT THERAPY:
Previous or concurrent cancer except
Concurrent NSAID therapy; washout period of 7 days
Concurrent enrollment in another clinical study
Concurrent use of anticholinergics
Concurrent use of anti-seizure drugs, with the exception of gabapentin for treatment of neuropathy
Any concurrent treatment that would compromise the study including but not limited to:
Concurrent somatostatin analogues are allowed provided that the dose has been stable (+/- 10 mg) for at least 8 weeks
Concurrent use of rifampin or ketoconazole
Concurrent treatment with any cytotoxic therapy
No prior or concurrent systemic or radiation therapy for the treatment of myeloma
Prior or concurrent use of erythropoietin is disallowed
Plan to administer concurrent radiation therapy now or for progressive symptoms during treatment
Concurrent therapy with any other investigational drug
Concurrent therapy given to treat cancer
Concurrent therapeutic intervention (including radiation therapy and NovoTTF).
Concurrent treatment with a non permitted drug
Concurrent spironolactone use
No concurrent herbal or unconventional therapy
Concurrent hormone replacement therapy
Participation in concurrent clinical trials evaluating treatment intervention(s)
Has a serious concurrent medical condition such as:
Medical History and Concurrent Diseases
Concurrent anti-cancer treatment in another investigational trial
Concurrent treatment with non-permitted drugs and other interventions
Patients for whom concurrent Adriamycin or gemcitabine chemotherapy is planned, unless on a concurrent protocol (such as a COG sponsored protocol)
Patient is participating in a concurrent treatment protocol
Concurrent or planned concurrent treatment with anticoagulants such as Coumadin or heparin, except to maintain patency of in dwelling catheters
Prior or concurrent therapy with somatostatin analogs is permitted for patients with secretory NET
Concurrent cancer therapy is not permitted.
Concurrent anti-platelet therapy
Concurrent treatment with any systemic chemotherapeutic agent
Concurrent neurodegenerative disease,
Concurrent investigational therapy given to treat cancer or concurrent participation in another clinical trial involving anti-cancer investigational drug.
Concurrent anti-cancer treatment in another investigational trial
Concurrent therapy with protocol-defined excluded medications
Concurrent treatment with a non-permitted drug
Patients receiving any concurrent immunosuppressants
Participants receiving any other cancer directed concurrent therapy; such as concurrent chemotherapy, radiotherapy, or hormonal therapy; concurrent treatment with bisphosphonates/denosumab is allowed but should be started before starting treatment on study
Concurrent administration of any other anti-tumor therapy
Patient is participating in a concurrent treatment protocol
concurrent use of anti-coagulant drugs
Treatment plan to include delivery of concurrent chemoradiotherapy
Serious concurrent illness:
Patients in cohort 2 being treated with concurrent HER2 therapy must have undergone treatment with the concurrent HER2 therapy selected by their attending physician for at least 3 weeks prior to initiation on this study
Patients who are receiving any cancer-directed concurrent therapy, such as concurrent chemotherapy, radiotherapy, or hormonal therapy while on study; concurrent treatment with bisphosphonates and denosumab is allowed for bony metastases but should be started before the first dose of neratinib
Prior or concurrent exposure to approved or investigational multiple myeloma treatments (concurrent treatment with bone-protecting agents (eg, bisphosphonates, denosumab), or steroids (not exceeding 10 mg prednisone per day or equivalent) are only allowed if given in a stable dose and for a nonmalignant condition; concurrent treatment with erythropoietin-stimulating agents (ESAs) are not allowed.)
Patients must be registered on the study within 5 weeks of completion of concurrent chemoradiation
Concurrent investigational therapy delivered over the period of treatment or observation (28 days post-RT) for dose limiting toxicity
Non-protocol concurrent hormonal therapy is not allowed
Concurrent treatment with a non-permitted drug.
No concurrent enrollment in another therapeutic protocol for the same diagnosis
Subject must understand that while they are on study they cannot have any concurrent curative therapy for their cancer other than what is outlined in the protocol
No other concurrent investigational treatment
A concurrent skin rash or skin condition requiring treatment with a prescription medication
Concurrent neoplasia requiring cytotoxic therapy
Concurrent therapy for cancer
Concurrent neoplasia requiring cytotoxic therapy
Concurrent radiation therapy, except for palliation of a single painful bone lesion or fracture.
Requirement for concurrent systemic glucocorticoid therapy at greater than physiologic replacement doses
Patients are allowed to be on another study concurrent with this protocol
Concurrent serious infection
Concurrent use of QT-prolonging medication
Concurrent treatment for cancer
Concurrent enrollment in another investigational clinical study
Medical History and Concurrent Diseases
Concurrent treatment with relevant doses of systemic glucocorticosteroids.
Significant concurrent disease.
Subjects who are considered to require concurrent therapy with another influenza antiviral medication.
Patients who are participating in a concurrent treatment protocol
Concurrent use of alternative cancer therapies
Concurrent treatment with bisphosphonates is permitted, however treatment must be initiated prior to the first dose of study therapy;
Have a concurrent major debilitating illness,
Concurrent use of bupropion
Previous or concurrent use of flibanserin
Not have: concurrent use of ethyol; severe cognitive compromise; known history of central nervous system (CNS) disease (e.g. brain metastases, seizure disorder); concurrent use of amifostine, concurrent abdominal radiotherapy; concurrent use of quinolone antibiotic therapy; chronic alcoholism (as determined by the investigator); known hypersensitivity to olanzapine; known cardiac arrhythmia, uncontrolled congestive heart failure or acute myocardial infarction within the previous six months; history of uncontrolled diabetes mellitus (stable insulin dose and/or stable oral hypoglycemic agent permitted); or have planned chemotherapy or radiation during the 7 days following study initiation
Receiving concurrent radiation therapy
Concurrent use of somatostatin
Are receiving concurrent radiation therapy (RT)
Concurrent breast related radiation therapy is allowed
Concurrent participation in another chemoprevention trial
Concurrent radiation, chemotherapeutic, or investigational therapy other than transplant related therapy
Concurrent enrollment in LCCC 1404
Concurrent cancer treatment of any kind is allowed, but the participant can also have completed all treatment
Concurrent antiandrogen therapy allowed but not required
Prior/concurrent radiation allowed
Patients receiving concurrent additional biologic therapy
Concurrent participation in other investigational studies allowed
Concurrent diuretic use
Be receiving concurrent radiotherapy or interferon.
Concurrent use of immunosuppressant medications
Concurrent therapy with other seizurogenic medications.
Completion of treatment with standard radiation (with or without concurrent therapy)
Concurrent therapy will be allowed
Patients who are participating in a concurrent treatment protocol
Medical History and Concurrent Diseases
